Skip to content
10-K

Annual Report

ROIVANT SCIENCES LTD. ROIV

0001140361-25-020715

← back to feed
Filed
May 29, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · May 21, 2025 679.81M sh
Stock Repurchased FY 2024 · Mar 31, 2025 $1.29B
Stock Repurchased FY 2024 · Mar 31, 2024 $0
Stock Repurchased FY 2024 · Mar 31, 2023 $0
Cash And Equivalents restated FY 2024 · Mar 31, 2024 $6.49B
Stockholders Equity FY 2024 · Mar 31, 2024 $5.97B
Current Liabilities FY 2024 · Mar 31, 2024 $266.76M
Total Liabilities FY 2024 · Mar 31, 2024 $773.95M
Current Assets FY 2024 · Mar 31, 2024 $6.73B
Total Assets FY 2024 · Mar 31, 2024 $7.22B
Shares Diluted FY 2024 · Mar 31, 2023 712.79M sh
Capex FY 2024 · Mar 31, 2023 $12.69M
Operating Cash Flow FY 2024 · Mar 31, 2023 −$843.39M
Eps Diluted FY 2024 · Mar 31, 2023 −$1.42
Eps Basic FY 2024 · Mar 31, 2023 −$1.42
Rd Expense restated FY 2024 · Mar 31, 2023 $454.06M
Net Income FY 2024 · Mar 31, 2023 −$1.01B
Operating Income restated FY 2024 · Mar 31, 2023 −$906.76M
Revenue restated FY 2024 · Mar 31, 2023 $31.53M